Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Quest Diagnostics Company Stats

Industry: Health Care Equipment & Services

Founded: 1967

Headquarters: Secaucus, New Jersey

Country/Territory: United States

Chief Executive Officer: James E. Davis

Employees: 48,000

Forbes Lists

#1228

Global 2000 (2024)

#540

World's Best Employers (2023)

America's Best Employers By State (2023)

#433

America's Best Large Employers (2023)Dropped off in 2024

#372

Best Employers for Women (2022)Dropped off in 2023

#253

Best Employers for New Grads (2022)Dropped off in 2023

#380

Best Employers for Diversity (2021)Dropped off in 2022

#309

America's Largest Public Companies (2018)

Quest Diagnostics Financial Summary

Select list year

Revenue

$9.3B

Assets

$14B

Profits

$842M

Sources

FactSet, Bloomberg, S&P Cap IQ; Forbes.

Quest Diagnostics (DGX) Stock Price Performance

SummaryAdditional DataAnalystsHistorical Quotes

Key Data

Previous Close

148.48

Open

147.59

Day’s Range

146.24 x 149.85

Volume

765,684

52 Week Range

119.59 x 150.59

Market Cap

$16.31B

P/E Ratio (ttm)

19.76

Forward P/E

16.30

Diluted EPS (ttm)

7.43

Dividends Per Share

2.88

Dividend Yield

2.02%

Ex-Dividend Date

Jul 8, 2024

Valuation Measures

P/E Ratio (ttm)

19.76

Forward P/E

16.30

Price to Sales (ttm)

1.77

Price to Book Value (ttm)

2.53

Price to Tangible Book Value (ttm)

N/A

Total Enterprise Value to EBIT (ttm)

15.71

Total Enterprise Value to EBITDA (ttm)

9.87

Total Enterprise Value to Total Revenue (ttm)

2.29

Markets data provided by S&P and by Xignite

Profitability Metrics

Gross Margin (ttm)

33.08%

Operating Margin (ttm)

14.29%

Net Margin (ttm)

9.11%

Return on Assets (ttm)

6.20%

Return on Equity (ttm)

14.15%

Revenue and Earnings Metrics

Revenue (ttm)

$9.29B

Revenue Per Share (ttm)

83.11

Revenue Growth (y/o/y)

-3.29%

EBITDA (ttm)

$1.78B

EBITDA Growth (y/o/y)

-0.62%

Diluted EPS (ttm)

7.43

Diluted EPS Growth (y/o/y)

9.35

Cash and Debt Metrics

Total Cash

$474M

Total Cash Per Share

4.27

Total Debt

$5.35B

Total Debt/Equity

81.76%

Current Ratio

0.97

All values as of most recently reported quarter unless otherwise noted.

Markets data provided by S&P and by Xignite

Consensus Recommendation

Outperform

Consensus Price

150.43

Range of Price Targets

136.00 to 165.00

Range of EPS

8.65 to 9.26

Consensus EPS

9.01

Consensus Revenue

$9.53B

Range of Revenue

$9.46B to $9.59B

Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.
EPS and Revenue estimates are for the next 12 months.

Markets data provided by S&P and by Xignite

DATE	OPEN	HIGH	LOW	CLOSE	ADJUSTED CLOSE	VOLUME
Jul 18, 2024	147.59	149.85	146.24	146.84	146.84	765,684
Jul 17, 2024	148.93	150.59	148.10	148.48	148.48	769,798
Jul 16, 2024	145.34	148.73	144.29	148.60	148.60	1,008,559
Jul 15, 2024	144.09	146.51	143.74	144.59	144.59	1,277,055
Jul 12, 2024	144.17	145.22	143.49	144.11	144.11	581,878
Jul 11, 2024	141.85	143.75	141.54	143.50	143.50	951,551
Jul 10, 2024	140.73	140.95	138.93	140.45	140.45	722,969
Jul 9, 2024	138.62	139.21	136.99	138.36	138.36	932,202
Jul 8, 2024	140.39	140.94	138.84	138.92	138.92	64,249
Jul 5, 2024	141.21	142.00	138.77	140.45	139.70	1,017,722